Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 12

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
, except per share amounts)

Three months endedJune 30,Six months endedJune 30,2025202420252024Revenue$213.1 $211.5 $409.0 $413.7 Cost of revenue61.3 64.4 123.0 128.9 Gross profit151.8 147.1 286.0 284.8 Costs and expenses:Research and development expense25.6 27.1 53.1 52.7 Sales and marketing expense71.9 72.8 141.1 142.2 General and administrative expense66.8 72.1 133.3 142.7 Goodwill and long-lived asset impairment charges316.7 11.6 316.7 11.6 Total operating expenses481.0 183.6 644.2 349.2 Operating loss(329.2)(36.5)(358.2)(64.4)Other income (expense):Interest income0.2 0.4 0.5 1.0 Interest expense(1.5)(0.8)(2.3)(1.3)Other(0.1)(0.3)— 1.6 Total other income (expense), net(1.4)(0.7)(1.8)1.3 Loss before income tax(330.6)(37.2)(360.0)(63.1)Income tax benefit(0.1)(0.5)(29.4)(0.4)Net loss$(330.5)$(36.7)$(330.6)$(62.7)Net loss per share:Basic and Diluted$(3.57)$(0.41)$(3.59)$(0.69)Weighted average shares outstanding:Basic and Diluted92.5 90.6 92.0 90.3 

See accompanying notes to Condensed Consolidated Financial Statements.

5

Table of Contents

 MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss (unaudited)

(in millions)

Three months endedJune 30,Six months endedJune 30,2025202420252024Net loss$(330.5)$(36.7)$(330.6)$(62.7)Change in unrealized loss on available-for-sale